Review Article

Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis

Marinella Patanè,1,2 Miriam Ciriaco,1,2 Serafina Chimirri,1,2 Francesco Ursini,3 Saverio Naty,3 Rosa Daniela Grembiale,3 Luca Gallelli,1,2 Giovambattista De Sarro,1,2 and Emilio Russo1,2

1 Department of Health Science, School of Medicine, University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy
2 Pharmacovigilance's Center Regione Calabria, University Hospital Mater Domini, 88100 Catanzaro, Italy
3 Rheumatology Research Unit and Ph.D. Program in Molecular Oncology, Experimental Immunology and Development of Innovative Therapies, University of Catanzaro, 88100 Catanzaro, Italy

Correspondence should be addressed to Luca Gallelli; gallelli@unicz.it

Received 17 March 2013; Revised 9 April 2013; Accepted 16 April 2013

Academic Editor: Raymond M. Quock

Copyright © 2013 Marinella Patanè et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor-α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure.

1. Introduction

Rheumatoid arthritis (RA) is a chronic and autoimmune disease affecting about 1% of people, with the highest incidence between 40 and 70 years [1]. Drugs able to reduce inflammation and cells activation may be used in the management of RA. In particular, nonsteroidal anti-inflammatory drugs (NSAIDs) as well as immunosuppressive agents (i.e., glucocorticoids), disease-modifying antirheumatic drugs (DMARDs), and agents that are able to block the proinflammatory cytokine tumor necrosis factor-α (anti-TNF-α) may be used (Table 1).

NSAIDs, acting on cyclooxygenases, are able to control the inflammation and the clinical symptoms [2–4], but not the disease’s progression; their use as monotherapy for a long time is limited for the development of adverse drug reactions (ADRs) [5].

Glucocorticoids (e.g., dexamethasone and prednisone) are anti-inflammatory and immune suppressor agents that are able to reduce the inflammation and the progression of RA, through the inhibition of cytokines secretion and osteoclasts activation [6–15].

However, even if they represent a first-line treatment in patients with RA, their use is limited for the development of serious ADRs such as loss of bone mass, increased risk of fractures, infections, diabetes and hypertension [16–18]. The DMARDs group, includes both nonbiological and biological drugs; between the DMARDs, methotrexate (MTX) due to
Table 1: Drugs used in the management of rheumatoid arthritis.

<table>
<thead>
<tr>
<th>Drugs for symptomatic control</th>
<th>DMARDs</th>
<th>Biological</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celecoxib</td>
<td>Azathioprine, Ciclosporin [hydroxy]-chloroquine, Leflunomide, Methotrexate, Sulphasalazine</td>
<td>Anti-TNF-α agents: infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol</td>
</tr>
<tr>
<td>Etoricoxib</td>
<td></td>
<td>Anti-IL: anakinra, Anti-IL-6: tocolizumb</td>
</tr>
<tr>
<td>Lumiracoxib</td>
<td></td>
<td>Anti-CD20: rituximab, Anti-CD80/86-CD28: abatacept</td>
</tr>
<tr>
<td>Parecoxib</td>
<td>Prednisone</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Disease-modifying antirheumatic drugs.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Use</th>
<th>Dosage</th>
<th>Adverse effects</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abatacept</td>
<td>Monotherapy in moderate severe RA or with DMARDs</td>
<td>500/1000 mg iv for 2 weeks then for 4 weeks</td>
<td>Headache, blood hypertension, nausea, infections respiratory system, vertigo, and severe infection</td>
<td>Modulator of T-lymphocyte activation</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>Moderate or severe AR</td>
<td>40 mg sc. for 2 weeks</td>
<td>Myositis, headache, rash, nausea, blood hypertension, hyperlipidemia, and higher plasma transaminases levels</td>
<td>Anti-TNF-α</td>
</tr>
<tr>
<td>Anakinra</td>
<td>Monotherapy in moderate/severe RA in patient with ≥1 DMARD not efficacy</td>
<td>100 mg/die sc.</td>
<td>Abdominal pain, diarrhea, headache, fever, and infections of respiratory system</td>
<td>Anti-IL-1</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Moderate or severe AR</td>
<td>400 mg sc. for 2 weeks then 200 mg for 2 weeks</td>
<td>Rash, headache, blood hypertension, fever, and asthenia</td>
<td>Anti-TNF-α</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Moderate or severe AR with DMARD</td>
<td>50 mg/weeks sc.</td>
<td>Pain into injection site, infections, headache, rash, vertigo, and asthenia</td>
<td>Anti-TNF-α</td>
</tr>
<tr>
<td>Golimumab</td>
<td>RA M/S with MTX</td>
<td>50 mg/month sc.</td>
<td>Blood hypertension, higher plasma transaminases levels, and vertigo, rhinitis</td>
<td>Anti-TNF-α</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Moderate or severe AR with MTX</td>
<td>3 mg/kg iv one time then on 2 and 6 weeks</td>
<td>Fever, headache, rash, myalgia, asthenia, dyspnea, and higher plasma transaminases levels</td>
<td>Anti-TNF-α</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Moderate or severe AR, with MTX in patient and without response to ≥1 anti-TNF-α agent</td>
<td>1000 mg iv in days 1 and 15 then at 24 weeks</td>
<td>Fever, nausea, hypotension, itching, and myelosuppression</td>
<td>Modulator of B-cell activation</td>
</tr>
</tbody>
</table>

its good safety and clinical efficacy, represents the first choice for the treatment of RA [19]. When a 6-month treatment with conventional drugs (NSAIDs, glucocorticoid, and DMARDs) is ineffective or when RA is severe (e.g., early destruction or unfavorable prognosis), the treatment with biological DMARDs may be started. A combination treatment between MTX and glucocorticoids or biological drugs is also often considered (Table 2) [20–22]. In patients with RA, the Food and Drug Administration (FDA) approved the use of anti-TNF-α (infliximab, adalimumab, golimumab, certolizumab, pegol, and etanercept) as combined therapies [23]. Previously, we documented that a multidrug treatment may be related to a higher development of ADRs and/or drug-drug interactions (DDIs) [24–42], and this represents a major issue during the clinical management of any disease requiring polytherapy. Based on this background, the aim of the present review is to describe the DDIs between MTX and the other drugs used in the treatment of patients with RA.

2. Methods

The Medline, PubMed, Embase, and Cochrane library databases were searched for articles published until June 30, 2012. Secondary search included articles cited in reference lists identified by the primary search. Records were first screened by title/abstract before full text articles were retrieved for eligibility evaluation. Remaining articles were then subjected to a citation search before a final hand search of all reference lists. Papers were deemed eligible if they included any form of words: “rheumatoid arthritis,” “antirheumatic drugs,” “NSAIDs,” “glucocorticoids,” “DMARDs,” “biologic drugs,” and “drug-drug interaction.” All citations were downloaded into Endnote software version 14, and duplicates were deleted. MP, MC, and FU screened all articles by title/abstract to determine their eligibility, and LG reviewed a random sample of 15% in order to evaluate the reliability of the selection process. In order to avoid a bias
of exclusion, the full text articles were retrieved following first round exclusions and were also subjected to two independent eligibility reviews (MP 100% and LG 15%), this time with perfect agreement. The studies evaluated as eligible were enclosed in the present review.

3. Methotrexate Pharmacology

3.1. Pharmacokinetic. After oral administration, MTX is rapidly adsorbed, with a T_max of 2 hours and a terminal half-life of 8–10 hours. In plasma, MTX binds reversibly to albumin (60–70%) and rapidly accumulates inside red blood cells through the reduced folate carrier. In red cells, MTX receives 2–5 glutamate moieties and is retained as MTX polyglutamates (MTXGlu) [43, 44]. The enzyme gamma-glutamyl hydrolase removes the terminal glutamate molecules; therefore, MTX returns to its monoglutamate form and can be transported out of the red cells by multidrug-resistant protein [43]. MTX is predominantly eliminated as an unmodified drug by the kidney (80%) via the human organic anion transporter-3 (HTO-3) in the renal proximal tubule.

3.2. Pharmacodynamic. MTX is an “antimetabolite” that is able to block the chain elongation of DNA leading to the arrest of cell cycle. Folic acid analogues, competitively and reversibly inhibit the enzyme dihydrofolate reductase (DHF reductase) that catalyzes the transformation of dihydrofolate acid (FH₂) into tetrahydrofolate acid (FH₄) (Figure 1).

FH₄, inside the cells, undergoes the addition of 6 glutamic-acid residues, by the enzyme folic-glutamate synthase to obtain FH₄(Glu)₆. Then, it is transformed into two molecules: N5,10-methylene-FH₄ and 10-formyl-FH₄ (Figure 1). N5,10-methylene-FH₄ acts as a donor of monocarboniose units in the reaction that forms thymidine monophosphate (dTMP) from deoxyuridine monophosphate (dUMP); this reaction is catalyzed by the enzyme thymidylate synthase.

Thymidine is required for the synthesis of DNA and RNA. MTX indirectly blocks the formation of dTMP by inhibiting DHF reductase. Furthermore, FH₂, which accumulates following the inhibition of DHF reductase, in turn inhibits thymidylate synthase (Figure 1). Through this mechanism, MTX blocks the synthesis of DNA and RNA and acts as an antimetabolite, mainly during the S-phase of cell cycle, by presenting a greater cytotoxic effect in cells with high turnover, for example, cancer cells [22]. Moreover, it has been also reported that MTX is able to inhibit the production of cytokines (e.g., IL-1), leukotriene B₄, and histamine [45, 46].

In this light, MTX is used to treat patients with hematological malignancies as well as patients with rheumatoid arthritis, juvenile rheumatoid arthritis, and skin disorders (e.g., psoriasis, dermatomyositis, systemic sclerosis, morphea, cutaneous sarcoidosis, and different types of eczema).

4. Methotrexate’s Interactions with Drugs Commonly Used in RA Treatment

DDIs represent the commonest causes of ADRs, particularly in the elderly and can be classified into two main groups pharmacokinetic or pharmacodynamic [52].
4 Advances in Pharmacological Sciences

Table 3: DDIs between MTX and NSAIDs.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs (indomethacin, ketoprofen, naproxen, and diclofenac)</td>
<td>Competition for tubular secretion via the HOAT-3</td>
<td>NSAIDs decrease the excretion of MTX with an increase in ADRs.</td>
<td>[47, 48]</td>
</tr>
<tr>
<td>COX-2 inhibitors Etoricoxib</td>
<td>Inhibition of HOAT-3</td>
<td>Decreased excretion of MTX with an increase in ADRs</td>
<td>[49]</td>
</tr>
<tr>
<td>Other COX-2 inhibitors (i.e., celecoxib and lumiracoxib)</td>
<td>-</td>
<td>No data</td>
<td>[50, 51]</td>
</tr>
</tbody>
</table>

4.1. MTX and NSAIDs. A recent Cochrane systematic review by Colebatch and coworkers [53] evaluating 8621 studies documented that only 17 publications reported a concurrent use of MTX and NSAID, but none reported ADRs on lung, liver, or renal function and no increase in MTX withdrawal or in other major toxicity. On the other hand, a pharmacokinetic DDI, on HOAT-3, has been described during the treatment with MTX plus NSAIDs, particularly with ketoprofen, indomethacin, naproxen, and diclofenac [47, 48]. Moreover, an experimental study has recently documented that etoricoxib is able to inhibit the HOAT-3 in a competitive and dose-dependent manner [49]; therefore, DDI could be hypothesized during the treatment with MTX.

In contrast, up to date no data have been published concerning a DDI between celecoxib and MTX [50, 51] (Table 3).

4.2. MTX and Glucocorticoids. An experimental study demonstrated that an oral pretreatment with dexamethasone reduces up to 53% of the biliary clearance of MTX, inducing a hepatocellular impairment [65].

Although liver toxicity has been reported in children with brain tumor treated with MTX and dexamethasone [66], definitive data have not been published concerning possible DDIs between MTX and glucocorticoids.

In agreement, Malysheva et al. [67] failed to report the development of DDIs during the concomitant treatment with MTX plus prednisolone.

4.3. MTX and DMARDs. The combination of MTX and either leflunomide or sulphasalazine in nonresponders RA patients reduced pain symptoms but induced an increase in serious ADRs. In particular, since pharmacokinetic DDIs were not reported in patients treated with MTX (mean dose 17.2 mg per week) plus leflunomide (100 mg daily for 2 days as a loading dose followed by 10 to 20 mg daily) [68], several papers reported an increase in both liver toxicity and blood dyscrasia (i.e., pancytopenia) (Table 4). In this light, the UK manufacturer suggests that the coadministration of MTX and leflunomide is not advisable [54–59]. In agreement Lee et al. [60] reported an increased risk of liver fibrosis in patients with RA treated with leflunomide plus methotrexate. However, the Smile study evaluating 2975 patients with RA, recently documented the safety of the association between MTX and leflunomide [69]. In contrast, Katchamart et al. [61] evaluating 19 clinical trials (2025 patients) documented that the concurrent treatment with MTX plus sulphasalazine is correlated with an increase in both liver and gastrointestinal toxicity (Table 4). Finally, even if sulphasalazine displaces MTX from its plasmatic albumin site, no net change in free MTX concentration or an increased risk of toxicity was underlined. This is probably due to the percentage (50%) of binding and the increased displacement would likely lead to an increased elimination sulphasalazine is a HOAT-1 and HOAT-3 inhibitors; therefore, it is able to inhibit the renal excretion of MTX [62]. However, the clinical impact of this DDI should be better investigated in clinical trials.

4.4. MTX and Immunosuppressant. Usually, cyclosporine administered as monotherapy can induce kidney toxicity; so it should be started at lower dose (Table 4). It was previously suggested that combined treatment with cyclosporine and other antirheumatic drugs, such as MTX, is very promising [78]. However, an open-label pharmacokinetic study published by Baraldo et al. [79] documented in 26 RA patients treated for 14 days with MTX (7.5 to 22.5 mg weekly) plus cyclosporine (1.5 mg/kg bid) a significant increase ($P < 0.01$) in mean area under the curve (AUC) of MTX (26%), with a significant decrease (80%; $P < 0.001$) of its active metabolite (7-hydroxymethotrexate). This DDI is related to a lower activity and a higher toxicity. In agreement, more recently, another study reported an increase in kidney ADRs (e.g., hypertension or increase in serum creatinine) in RA patients treated with cyclosporine plus MTX in comparison to patients receiving cyclosporine alone [63]. In contrast, Sarzi-Puttini et al. [64] did not show any increase in ADRs in patients treated with cyclosporine (3 mg/kg) + MTX (from 7.5 to 10 mg weekly) in respect to patients treated with cyclosporine alone. At the moment, no DDIs during the treatment with MTX + mycophenolate mofetil have been reported; therefore, this coadministration seems to be well tolerated (Table 4).

Table 4: MTX’s interaction with DMARDs and immunosuppressant.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leflunomide and sulphasalazine</td>
<td>Increase in liver and blood toxicity</td>
<td>[54–62]</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Renal toxicity</td>
<td>[63]</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>No data</td>
<td>[64]</td>
</tr>
</tbody>
</table>
Table 5: DDIs between MTX’s and biological drugs.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab, adalimumab,</td>
<td>Increased risk of</td>
<td>[70–72]</td>
</tr>
<tr>
<td>golimumab, and certolizumab</td>
<td>infections</td>
<td></td>
</tr>
<tr>
<td>pegol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>No DDIs</td>
<td>[72]</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>No DDIs</td>
<td>[73]</td>
</tr>
<tr>
<td>Tocilizumab, certolizumab</td>
<td>No DDIs</td>
<td>[74–76]</td>
</tr>
<tr>
<td>pegol, and golimumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abatacept</td>
<td>No DDIs</td>
<td>[77]</td>
</tr>
</tbody>
</table>

4.5. MTX and Biological Drugs. The cotreatment with anti-TNF-α plus MTX induces synergistic effects on the immunosuppressive activity of MTX, even if this treatment may be related to an increased risk of infections [70–72]. However, no pharmacokinetic DDIs were documented during the treatment with etanercept (subcutaneous dose) plus MTX (oral dose) [72].

Similarly, several clinical trials performed in patients with active RA without an adequate response to MTX; the addition of adalimumab to MTX achieved an improvement of RA symptoms, without the development of pharmacokinetic DDIs [73, 80, 81].

However, this treatment may be related to an increase in liver enzymes; therefore, it is prudent to increase the frequency of liver enzyme monitoring in patients receiving this cotreatment. Other data documented the absence of pharmacokinetic DDIs during the contemporary administration of MTX plus rituximab [82], tocilizumab [74], certolizumab pegol [75], or golimumab [76] (Table 5).

Abatacept, a modulator of T-lymphocyte activation, approved for the treatment of active RA, has been recommended for nonresponder patients to DMARDs such as MTX or anti-TNF-α [77]. A recent Cochrane review demonstrated significant lower risk of serious ADRs during the treatment with abatacept in respect to other biological drugs [83]. Since an interaction between this drug and MTX has not been established, the ACR recommend the coadministration of abatacept and MTX; abatacept in monotherapy is not recommended due to the lack of data.

5. Discussion and Conclusion

The depletion of folate and the inability of the cells to synthesize DNA at the same time can explain the antineoplastic/antirheumatic effects possessed by MTX and also its toxicity. The suppressive effect of MTX on hematopoietic system and the risk of fibrosis, cirrhosis, or gastrointestinal ulcer require a frequent monitoring of functional parameters. The supplementation of folic acid is helpful to reduce the MTX’s toxicity [84]. The importance of pharmacovigilance studies in patients treated with MTX is also related to risk of DDIs that may increase the MTX’s toxicity. After absorption, MTX is bounded to the serum albumin for its distribution and therefore can be displaced by other drugs that are coadministered. The kidney clearance of MTX may be reduced by NSAIDs or DMARDs, while the risk of liver toxicity and bone marrow suppression is increased during the treatment with drugs with similar ADRs [84, 85].

In conclusion, during the treatment with MTX, it is necessary to keep in consideration the risk of DDIs that are able to increase the risk of hepatotoxicity, nephrotoxicity, myelotoxicity, and other toxic effects.

6. Summary

(i) DDIs are very important and must be timely recognized in order to prevent the development of ADRs or therapeutic failure.

(ii) Low dose of MTX represents a safe treatment for patients with RA receiving other treatments with antirheumatic drugs, since some DDIs may occur.

(iii) The association MTX + NSAIDs or etoricoxib may be related to an increase of MTX toxicity.

(iv) The association MTX + leflunomide or MTX + sulphasalazine may induce liver toxicity and/or blood toxicity.

(v) Very few data have been published regarding the association between MTX and biological DMARDs.

(vi) In order to prevent the development of DDIs, it is important to decrease the dosage of MTX or of the drugs that are coadministered.

(vii) In the presence of ADRs during the treatment, it is useful to evaluate the plasma concentration of the drugs.

Conflict of Interests

The authors have no conflict of interests to be declared.

Acknowledgments

Funds needed to purchase articles for this survey were granted by “Rete Regionale di informazione sul farmaco: informazione, formazione, e farmacovigilanza” Project Sponsored by Regione Calabria on the Behalf of Agenzia Italiana del Farmaco (AIFA).

References


J. Zeidler, H. Zeidler, and J. M. Graf von der Schulenburg, "Tre-


[74] RoActemra (Tocilizumab), Roche Registration Ltd. Summary of product characteristics, January 2009.


[76] Simponi (Golimumab), Centocor Ortho Biotech Inc. US Prescribing information, April 2009.


